Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SOX4
REST API REST API
Homo sapiens
SOX4 is differentially expressed in 400 experiments: 161 organism parts: liver, thymus, ... (159 more);, 277 disease states: normal, acute myeloid leukemia, ... (275 more);, 151 cell types 528 cell lines 76 compound treatments and 87 other conditions.
Orthologs sox4a (Danio rerio)   Sox4 (Mus musculus)   sox4b (Danio rerio)   Q4H2S1_CIOIN (Ciona intestinalis)   Sox14 (Drosophila melanogaster)   sox12 (Xenopus laevis)   SOX4 (Bos taurus)   SOX4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein stabilization, protein binding, positive regulation of translation, regulation of transcription, DNA-dependent, cytoplasm, negative regulation of cell proliferation, transcription, DNA-dependent, positive regulation of cell proliferation, negative regulation of apoptosis, regulation of protein stability, positive regulation of apoptosis, glucose homeostasis, glial cell development, positive regulation of transcription from RNA polymerase II promoter, nucleus, heart development, somatic stem cell maintenance, canonical Wnt receptor signaling pathway, negative regulation of protein export from nucleus, positive regulation of Wnt receptor signaling pathway, positive regulation of transcription, DNA-dependent, mitochondrion, DNA damage response, detection of DNA damage, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, neural tube formation, cellular response to glucose stimulus, pro-B cell differentiation, glial cell proliferation, kidney morphogenesis, cardiac ventricle formation, spinal cord development, atrial septum primum morphogenesis, cardiac right ventricle morphogenesis, positive regulation of canonical Wnt receptor signaling pathway, positive regulation of insulin secretion, spinal cord motor neuron differentiation, limb bud formation, skeletal system development, ventricular septum morphogenesis, sympathetic nervous system development, negative regulation of cell death, endocrine pancreas development, T cell differentiation, negative regulation of protein ubiquitination, sequence-specific DNA binding transcription factor activity, neuroepithelial cell differentiation, RNA polymerase II transcription coactivator activity, noradrenergic neuron differentiation, transcription regulatory region sequence-specific DNA binding, core promoter sequence-specific DNA binding, positive regulation of N-terminal peptidyl-lysine acetylation, mitral valve morphogenesis, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, nucleic acid binding transcription factor activity, ascending aorta morphogenesis
InterPro Term HMG_HMG1/HMG2, SOX-12/11/4a
UniProt Accession Q06945
Search EB-eye ENSG00000124766
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-22541, ... (41 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
K562
3
E-MTAB-37, E-GEOD-24147, E-GEOD-96
SW480
1
3
E-GEOD-18005, E-MTAB-37, E-MEXP-1014, E-GEOD-2509
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
HL-60
1
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37, E-GEOD-96
A549
2
E-GEOD-3202, E-GEOD-6013
HT1080
2
E-MTAB-37, E-GEOD-20089
522 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (66 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-3920, E-GEOD-96, E-GEOD-19240
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
CD8+ T cell
1
3
E-AFMX-5, E-GEOD-19069, E-MTAB-25, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
bronchial epithelial
2
E-AFMX-5, E-MTAB-25
mononuclear cell
1
2
E-GEOD-6053, E-GEOD-7307, E-MEXP-66
145 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (85 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-TABM-26, E-MEXP-1327, E-MTAB-62, E-MEXP-2034
chronic myelogenous leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-MTAB-57
lung adenocarcinoma
3
E-MTAB-62, E-GEOD-2514, E-MEXP-231
AIDS-KS, HIV+, nodular (late) stage
2
2
E-MTAB-62, E-MEXP-66
benign prostatic hyperplasia
2
E-MEXP-1243, E-MEXP-2034
271 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, ... (44 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-3183, E-GEOD-3284, E-GEOD-5339
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
nebivolol
1
E-GEOD-3356
eicosapentaenoic acid
1
E-MEXP-1389
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
NaOH
1
E-MEXP-2590
70 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
37
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (10 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-GEOD-6431, ... (8 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, ... (14 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, E-TABM-440, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (39 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-22541, E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (7 experiments)

pt
studied in E-GEOD-21653

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.411 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM